Abstract: P371
Type: Poster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Background: Objective measures of upper limb, lower limb and cognitive function are commonly used to assess MS patients. Although these measures provide an assessment of function and disability, they may not reflect how patients perceive their own ability.
Objective: To understand how patients' perceptions of upper extremity, lower extremity and cognitive function are related to objective functional performance measures.
Methods: MS PATHS is a collaborative network of ten healthcare institutions in the US and Europe. During routine office visits, patients used the Multiple Sclerosis Performance Test (MSPT), an iPad-based device, to complete 12 scales from the Quality of Life in Neurological Disorders (Neuro-QoL) instrument and electronic adaptations of the MSFC: a processing speed test (PST); manual dexterity test (MDT); and walking speed test (WST). The relationship of the subjective self-reported scales and objective functional scales was assessed using scatterplots and Spearman's rank correlations.
Results: The sample comprised 1353 patients. Mean (SD) age was 48.9 yrs (12.0), mean (SD) disease duration 12.2 yrs (9.4), 72% were female and 85% were white. Mean (SD, range) Neuro-QoL upper extremity t-score was 43.3 (9.3, 22.3-56.8), mean (SD, range) Neuro-QoL lower extremity t-score was 44.6 (10.7, 15.7-62.3) and mean (SD, range) Neuro-QoL cognitive function t-score was 45.3 (9.6, 22.9-68.3). Mean (SD, range) PST was 45.9 correct (13.2, 4-86), mean (SD, range) MDT was 28.8 secs (7.1, 17.2-55.8) and mean (SD, range) WST was 8.1 secs (5.4, 2-52.5). There were moderately strong (p< 0.001) correlations between Neuro-QoL upper extremity t-scores and the MDT (rs=-0.56), and Neuro-QoL lower extremity t-scores and the WST (rs=-0.48). A weaker correlation was observed between Neuro-QoL cognitive function t-scores and the PST (rs=0.29, p< 0.01).
Conclusions: Consistent with previous findings, self-reported cognitive status shows a weak correlation with cognitive performance measures (Benedict et al. 2008). This suggests the PST provides important information in determining when more comprehensive evaluations are needed to clarify the impact of cognitive dysfunction on QoL, function and employment. The stronger correlations observed between Neuro-QoL scores and the functional performance measures of upper and lower extremity function confirm the utility of the self-reported assessment, but their modest range indicate self-report and performance yield distinct information.
Disclosure: Project funded by Biogen, Inc.
Author disclosures:
Deborah Miller has received consulting fees from Hoffmann-Roche and Biogen.
Robert Naismith has received consulting fees and/or honoraria from Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis and Teva.
Carrie Hersh has received speaking and consulting fees from Genzyme and Teva, and grant funding from Genentech.
Megan Hyland is employed by the University of Rochester which receives funding from Biogen, Chugai and Novartis.
Carl de Moor, Glenn A. Phillips, James R. Williams and Richard Rudick are employees of, and stockholders in, Biogen.
Lauren Krupp has received consultant fees from EMD Serono, Projects in Knowledge, Novartis, Pfizer (for serving on a DSMB), Biogen, PK Law and Teva Neurosciences; Royalty payments from Abbvie Inc. and Grifols World Wide Services; and research grant support from Novartis, Teva Neurosciences, Biogen, NIH, National Multiple Sclerosis Society, Department of Defense and the Lourie Foundation.
Abstract: P371
Type: Poster
Abstract Category: Clinical aspects of MS - 7 MS symptoms
Background: Objective measures of upper limb, lower limb and cognitive function are commonly used to assess MS patients. Although these measures provide an assessment of function and disability, they may not reflect how patients perceive their own ability.
Objective: To understand how patients' perceptions of upper extremity, lower extremity and cognitive function are related to objective functional performance measures.
Methods: MS PATHS is a collaborative network of ten healthcare institutions in the US and Europe. During routine office visits, patients used the Multiple Sclerosis Performance Test (MSPT), an iPad-based device, to complete 12 scales from the Quality of Life in Neurological Disorders (Neuro-QoL) instrument and electronic adaptations of the MSFC: a processing speed test (PST); manual dexterity test (MDT); and walking speed test (WST). The relationship of the subjective self-reported scales and objective functional scales was assessed using scatterplots and Spearman's rank correlations.
Results: The sample comprised 1353 patients. Mean (SD) age was 48.9 yrs (12.0), mean (SD) disease duration 12.2 yrs (9.4), 72% were female and 85% were white. Mean (SD, range) Neuro-QoL upper extremity t-score was 43.3 (9.3, 22.3-56.8), mean (SD, range) Neuro-QoL lower extremity t-score was 44.6 (10.7, 15.7-62.3) and mean (SD, range) Neuro-QoL cognitive function t-score was 45.3 (9.6, 22.9-68.3). Mean (SD, range) PST was 45.9 correct (13.2, 4-86), mean (SD, range) MDT was 28.8 secs (7.1, 17.2-55.8) and mean (SD, range) WST was 8.1 secs (5.4, 2-52.5). There were moderately strong (p< 0.001) correlations between Neuro-QoL upper extremity t-scores and the MDT (rs=-0.56), and Neuro-QoL lower extremity t-scores and the WST (rs=-0.48). A weaker correlation was observed between Neuro-QoL cognitive function t-scores and the PST (rs=0.29, p< 0.01).
Conclusions: Consistent with previous findings, self-reported cognitive status shows a weak correlation with cognitive performance measures (Benedict et al. 2008). This suggests the PST provides important information in determining when more comprehensive evaluations are needed to clarify the impact of cognitive dysfunction on QoL, function and employment. The stronger correlations observed between Neuro-QoL scores and the functional performance measures of upper and lower extremity function confirm the utility of the self-reported assessment, but their modest range indicate self-report and performance yield distinct information.
Disclosure: Project funded by Biogen, Inc.
Author disclosures:
Deborah Miller has received consulting fees from Hoffmann-Roche and Biogen.
Robert Naismith has received consulting fees and/or honoraria from Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis and Teva.
Carrie Hersh has received speaking and consulting fees from Genzyme and Teva, and grant funding from Genentech.
Megan Hyland is employed by the University of Rochester which receives funding from Biogen, Chugai and Novartis.
Carl de Moor, Glenn A. Phillips, James R. Williams and Richard Rudick are employees of, and stockholders in, Biogen.
Lauren Krupp has received consultant fees from EMD Serono, Projects in Knowledge, Novartis, Pfizer (for serving on a DSMB), Biogen, PK Law and Teva Neurosciences; Royalty payments from Abbvie Inc. and Grifols World Wide Services; and research grant support from Novartis, Teva Neurosciences, Biogen, NIH, National Multiple Sclerosis Society, Department of Defense and the Lourie Foundation.